Lommatzsch P K
Klin Monbl Augenheilkd. 1979 Jun;174(6):948-58.
From 1964 to 1976 a number of 131 patients, suffering from melanoma of the choroid have been treated with 106Ru/106Rh beta-ray applicators. In 81 cases (61.8%) this treatment has been successful. 26 eyes (19.9%) had to be enucleated in spite of the irradiation. 24 patients (18.3%) died, 13 of them of metastases. Only in 46 patients, out of 81, we have reached total destruction of the tumor with flat chorioatrophic scar. In 27 cases visual acuity of 1.5 to 0.5 could be preserved. Radiogenic late complications in the capillary system with disturbances of the retinal blood circulation were the cause of visual deterioration. The 107 surviving patients were controlled during a period of 6.5 years in the average. Survival rate 91.2% after 5 and 84% after 10 years. Another group of 214 patients with melanoma of the choroid, who had been treated from 1955 to 1970 by enucleation reached a survival rate of 72% after 5 years. Treatment with 106Rh beta-irradiation therefore leads to no increased danger of metastases. The following indications for this treatment are suggested: 1. Prominence of the tumor not exceeding 5 mm, largest diameter at its base not more than 15 mm. 2. Distance of the dorsal edge of the tumor at least 1-2 optic disc diameters from the nerve head. 3. Peripheral delimitation against the ciliary body. 4. No tumor growth outside the eye.
1964年至1976年期间，131例脉络膜黑色素瘤患者接受了106Ru/106Rhβ射线敷贴器治疗。其中81例（61.8%）治疗成功。尽管进行了放射治疗，仍有26只眼（19.9%）不得不摘除眼球。24例患者（18.3%）死亡，其中13例死于转移。在81例患者中，只有46例肿瘤完全破坏，形成扁平的脉络膜萎缩性瘢痕。27例患者的视力得以保留，在1.5至0.5之间。视网膜血液循环紊乱导致的毛细血管系统放射性晚期并发症是视力下降的原因。107例存活患者平均接受了6.5年的随访。5年生存率为91.2%，10年生存率为84%。另一组214例脉络膜黑色素瘤患者，在1955年至1970年期间接受了眼球摘除术，5年生存率为72%。因此，106Rhβ射线照射治疗不会增加转移的风险。建议该治疗的适应症如下：1.肿瘤突出不超过5mm，底部最大直径不超过15mm。2.肿瘤背侧边缘距视神经乳头至少1-2个视盘直径。3.与睫状体的周边界限。4.眼外无肿瘤生长。
